CN106038612A - Pharmaceutical composition for protecting eyesight as well as preparation method and application thereof - Google Patents
Pharmaceutical composition for protecting eyesight as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN106038612A CN106038612A CN201610500492.XA CN201610500492A CN106038612A CN 106038612 A CN106038612 A CN 106038612A CN 201610500492 A CN201610500492 A CN 201610500492A CN 106038612 A CN106038612 A CN 106038612A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- pharmaceutical composition
- raw material
- weight portions
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a pharmaceutical composition for protecting eyesight, which is prepared from lutein, haematococcus pluvialis, vitamin E, vitamin C and zinc gluconate as raw material components in proper proportion. The pharmaceutical composition is good in safety and free of toxic or side effect; and moreover, the lutein, astaxanthin provided by the haematococcus pluvialis, vitamin E, vitamin C and zinc gluconate are synergistic, thereby being favorable for enhancing the physiological function of the eye crystal, preventing eye aging, relieving eye strain and improving eyesight so as to treat multiple eye diseases, such as cataract, macular degeneration and diabetic retinopathy. The preparation method comprises the following steps: grinding and mixing all raw material components to obtain mixed powder; adding the mixed powder into ethanol to prepare wet particles; and drying and finishing the wet particles so as to finally obtain the pharmaceutical composition. The effective ingredients of all raw materials are kept to the maximum extent, and the curative effect is relatively good.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to a kind of pharmaceutical composition protecting eye eyesight and preparation side thereof
Method and application.
Background technology
Modern works every day before computer, long-time excess eye-using, will feel eyestrain, and eyes are dry and astringent, ache, regard
Thing obscures, and this is a kind of self-protection measure of eyes in fact.Eyes things to be seen clearly, light must fall at macula retinae
District, but the high light after focusing on falls to damage the cone cell of macular area at macular area for a long time.Eyes are poisoned in order to avoid light, long
After time eye, eyes do not fall at macular area with regard to light regulating, and just generation eyes are fuzzy aches and eyestrain, long term ocular fatigue meeting
Causing visual deterioration, degeneration of macula is the most blind.
Senile degeneration of macula is modal reason in old people's diseases causing blindness, is divided into atrophic type and exudative type two kinds.
Owing to choriocapillary atrophy, glass-film thicken and can cause atrophic type Age related macular with retinal pigment epithelium atrophy etc.
Degeneration；Exudative type pigment epithelium has serosity or hemorrhage.
Environmental hazard was increasingly severe in recent years, and ozone layer is destroyed, and the ultraviolet in sunlight is increasingly stronger, and with
The growth at age, eye lens is oxidized easily all the more, some eye lens metabolism disorders, causes crystalline lens egg
White matter degeneration and there is muddiness, referred to as cataract.The crystalline lens that cataract patient is muddy obstructs light and projects on the retina, makes
Object cannot be seen clearly.
Diabetic retinopathy is most important performance in diabetic microangiopathy, is that one has specificity
The retinopathy changed, is one of the severe complication of diabetes.Clinical fundus Oculi Manifestations is retinal capillary microangioma
Being formed, vasodilation, leaktightness of wall of tubes causes retinal edema, oozes out, hemorrhage, and then occurs blood capillary and small artery inaccessible,
Retinal ischemia, retinal neovascularization grows, and new vessels causes retina and massive vitreous hemorrhage, along with fibrous tissue
Propagation, forms proliferative vitreoretinopathy, and then traction detachment of retina occurs, can cause vision in various degree
Go down or metamorphopsia.
The poisonous side effect of medicine that traditional protection eyes improve vision is big, unsuitable long-term taking.And drug greatly simply carries
For human eye's desired nutritional, alleviate asthenopia, only visual performance is had health-care effect, or the limitednumber for the treatment of ophthalmic.
In order to reduce the toxic and side effects of protection eye eyesight medicine, Chinese patent CN103110096A discloses that " one subtracts
Light eyestrain, the nutrient and healthcare products of improving eyesight ".In these health product, formula uses multiple natural mineral matter and herbaceous plant extract,
There is supplementary eye nutrition, alleviate eyestrain, improve effect of vision.But this invention is relieving eye strain, dialogue
The oculopathy such as cataract do not have effect.Chinese patent CN104824650A discloses " a kind of eye protection health product ", and these health product are with natural
Animals and plants extract is raw material, with prevention, nyctalopia, vision decline, can effectively protect the health of eyes, and protection regards
Power；But the disease of eye that senile degeneration of macula, diabetic retinopathy etc. cause can not be treated.
Summary of the invention
In order to solve the problems referred to above that prior art exists, the invention provides that a kind of safety is good, have no side effect, energy
Pharmaceutical composition of protection eye eyesight enough treating multiple disease of eye and its preparation method and application.Guarantor of the present invention
Protect the pharmaceutical composition of eye eyesight, it is possible to effectively relieving eye strain, the weak stravismus of pre-child-resistant, myopia, it is comprehensive that treatment flies mosquito
The disease of eye such as disease, cataract, degeneration of macula, diabetic retinopathy, retinitis pigmentosa.
The technical solution adopted in the present invention is:
A kind of pharmaceutical composition protecting eye eyesight, raw material components includes:
Phylloxanthin, 60-140 weight portion；
Haematocoocus Pluvialls, 145-255 weight portion；
Vitamin E, 40-80 weight portion；
Vitamin C, 65-135 weight portion；
Zinc gluconate, 45-95 weight portion.
The raw material components of the pharmaceutical composition of further preferred described protection eye eyesight includes:
Phylloxanthin, 80-120 weight portion；
Haematocoocus Pluvialls, 175-230 weight portion；
Vitamin E, 50-70 weight portion；
Vitamin C, 85-115 weight portion；
Zinc gluconate, 60-80 weight portion.
The raw material components of the pharmaceutical composition of further preferred described protection eye eyesight includes:
Phylloxanthin, 100 weight portions；
Haematocoocus Pluvialls, 200 weight portions；
Vitamin E, 60 weight portions；
Vitamin C, 100 weight portions；
Zinc gluconate, 70 weight portions.
The raw material components of the pharmaceutical composition of further preferred described protection eye eyesight is also added with 70-140 weight portion and fills out
Fill agent, 50-80 part by weight of disintegrant, 20-40 parts by weight of binder and 2-6 weight portion lubricant.
It is dilute that the raw material components of the pharmaceutical composition of further preferred described protection eye eyesight is also added with 180-260 weight portion
Release the mixture of one or more in agent, 10-30 weight portion cosolvent and 40-70 parts by weight Emulsifier.
Described filler is microcrystalline Cellulose, sorbitol, Macrogol 4000, polyethylene glycol 6000, mannitol, compressibility
The mixture that one or more in starch, dextrin, lactose, starch, modified starch form with arbitrary proportion；
Described disintegrating agent is polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, hydroxyacetic acid
The mixture that one or more in Starch Sodium or carboxymethyl starch sodium form with arbitrary proportion；
Described binding agent is hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, polyvidone, methylcellulose, hydroxypropyl
The mixture that one or more in cellulose, ethyl cellulose, gelatin, carbomer or starch slurry form with arbitrary proportion；
Described lubricant is magnesium stearate, Pulvis Talci, micropowder silica gel, silicon dioxide, PEG6000, fumaric acid sodium, lauryl alcohol
The mixture that one or more in magnesium sulfate or sodium laurylsulfate form with arbitrary proportion.
Described diluent be glycerol, sorbitol, decanoyl/octanoyl glycerides, soybean oil, PEG400 one or more with arbitrarily
The mixture of ratio composition；
Described cosolvent is glycerol, polyvidone, cyclodextrin, isopropanol, ethylenediamine, lactic acid, polysorbate 20, Polysorbate
85, the mixture that one or more in polypropylene glycol form with arbitrary proportion；
Described emulsifying agent is sodium lauryl sulphate, dodecylbenzene sodium sulfonate, Stepanol MG, myristyl sulfur
One in acid sodium, lecithin, emulsifing wax, Cera Flava, casein, ethylene glycol monostearate, polysorbate 20, polysorbate 85
Or several with arbitrary proportion composition mixture.
A kind of method of pharmaceutical composition preparing described protection eye eyesight, comprises the steps:
(1) weighing each raw material components respectively, after pulverizing respectively, obtaining granularity is each raw material fine powder of 60-100 purpose；
(2) carry out described each raw material fine powder being sufficiently mixed uniformly, obtain the drug regimen of described protection eye eyesight
Thing.
The method of the pharmaceutical composition of the protection eye eyesight described in another kind of preparation, comprises the steps:
(1) phylloxanthin, Haematocoocus Pluvialls, vitamin E, vitamin C, zinc gluconate are weighed respectively, after pulverizing respectively,
Obtaining granularity is each raw material fine powder of 60-100 purpose；
(2) carry out described for step (1) each raw material fine powder being sufficiently mixed uniformly, obtain compound；
(3) in step (2) described compound, it is sequentially added into described diluent, cosolvent and emulsifying agent, obtains described
The pharmaceutical composition of protection eye eyesight.
Described pharmaceutical composition is any one in tablet, pill, capsule, by adding different auxiliary material, according to
Clinical needs, are respectively prepared different dosage form by described pharmaceutical composition.Described tablet is common compressed tablet, coated tablet, sugar
Any one of garment piece, Film coated tablets or Sublingual tablet；Described capsule is any one of hard capsule or soft capsule.
Described pharmaceutical composition is for preparing the application in protection eye eyesight medicine.
For the ease of understanding the present invention, below the raw material in the present invention and drug effect are further elaborated.
Phylloxanthin is one of nutrition important in human retina, at the macula area (center of vision) of eye retina
Contain with in crystalline lens, particularly the macula area phylloxanthin containing high concentration.Phylloxanthin cannot be synthesized voluntarily by human body, it is necessary to source
In food absorption or breast milk, eventually enter into crystalline lens and macula retinae portion, play anti-oxidation efficacy, neutralize harmful freedom
Base, filters the blue light harmful to eyes.Phylloxanthin has preventive effect to senile retinal macular degeneration, improves old people's vision
Decline, the blindness causing disease that prevention senile degeneration of macula is caused.Phylloxanthin in eyes has filtration to ultraviolet, can avoid
The injury to eye eyesight that the ultraviolet launched by daylight, computer etc. is caused.Phylloxanthin can also reduce cataractous
Incidence rate, has and alleviates internal and skin degenerative senile speckle danger, regulates blood fat, delays arteriosclerosis, anticancer grade to act on.
Haematocoocus Pluvialls is called again the raw Haematococcus Pluvialis in lake or lake hemopoietic ball algae, is a kind of chlorella generally existed, extensively deposits
It is in nature, without any toxic.Rich in astaxanthin in Haematocoocus Pluvialls, content is 1.5%-3.0%, is in nature
Produce the best biological of natural astaxanthin, be counted as " concentrate " of natural astaxanthin.Astaxanthin is the one of carotenoid
Kind, for a kind of stronger Natural antioxidant, topmost function is to remove free radical, improves flight against senium of human body ability.Natural
Astaxanthin can penetrate blood brain barrier, blood pancreas barrier, this three big mankind's main barrier of blood-testis barrier, and is uniquely to wear
The carotenoid of blood brain barrier, is therefore possible to act on brain cell and the unique Carotenoids of eyeball retina thoroughly.Shrimp
Blue or green element has the effects such as protection skin and eyes, opposing radiation, cardiovascular Aging, senile dementia and cancer.The old and feeble master of human body
If caused by the oxidation that free radical is caused.Astaxanthin, as the special molecular configuration of Haematococcus Pluvialis extract, can pass through
Human body cell outer wall, the oxygen-derived free radicals in direct scavenger cell, strengthen cell regeneration ability, maintain function of human body balance and reduce
The accumulation of senile cell, protection cell and DNA are healthy from inside to outside.Astaxanthin is easy to, by blood brain barrier and cell membrane, to have
Prevent to effect the damage of amphiblestroid oxidation and photoreceptor cell，photosensory cell, especially all good to the effect of macular degeneration.
Vitamin E can suppress the lipid peroxidation in ocular lens body to react, and makes peripheral vasodilation, improves blood circulation,
Pre-myopic-preventing generation and development.
Vitamin C is a kind of antioxidant, can protect other antioxidants simultaneously, such as vitamin E, prevent radical pair
The lenticular injury of eye, relieving eye strain, improves vision.
Zinc gluconate is dissociated into zinc ion and gluconic acid in vivo, participates in ribonucleic acid and the conjunction of DNA (deoxyribonucleic acid)
Become, thus wound healing can be promoted, promote growth, promote internal zinc enzyme function.Zinc gluconate can improve children intelligence,
Accelerate growth promoter, prevent and treat dysplasia, improve the sensitivity of the sense of taste, promote appetite, enhancing body anti pathologic immunity ability and wound
The regeneration capacity of injured tissue.Zinc element can strengthen children and youth height and body weight, improves the sensitivity of optic nerve, improves vision
With promotion vision, pre-myopia prevention, amblyopia and hypermetropia occur.Zinc gluconate is maintenance organ and the weight of sexual function normal development
Wanting material, health, fitness and prenatal and postnatal care with human body have close relationship.
The invention have the benefit that
The pharmaceutical composition of protection eye eyesight of the present invention, by using phylloxanthin, Haematocoocus Pluvialls, vitamin
E, vitamin C, zinc gluconate are as raw material components and carry out suitable proportioning, the pharmaceutical composition finally prepared, safety
Property good, have no side effect, and phylloxanthin, Haematocoocus Pluvialls provide astaxanthin, vitamin E, vitamin C, zinc gluconate
Work in coordination with between each component and play a role, be conducive to strengthening the physiological function of eyes crystal, prevent eyes aging, alleviate eyes tired
Labor, improves vision, thus can not only the weak stravismus of pre-child-resistant, myopia, treatment flies mosquito syndrome, cataract, degeneration of macula, sugar
The multiple disease of eye such as urine characteristic of disease retinopathy, retinitis pigmentosa.Additionally, the medicine of protection eye eyesight of the present invention
The preparation method of compositions, pulverizes, is mixed to get mixed powder by being carried out by each raw material components, then mixed powder is added ethanol
Make wet grain, wet grain drying, granulate, final prepared described pharmaceutical composition so that the effective ingredient of various raw materials is able to
Big reservation, curative effect is preferable.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is described in detail, represents 10g with 1 weight portion in following example.
Embodiment 1
The present embodiment provides a kind of pharmaceutical composition protecting eye eyesight, and raw material components includes:
Phylloxanthin, 60 weight portions；
Haematocoocus Pluvialls, 255 weight portions；
Vitamin E, 40 weight portions；
Vitamin C, 135 weight portions；
Zinc gluconate, 45 weight portions.
The preparation method of the pharmaceutical composition of described protection eye eyesight, comprises the steps:
(1) weighing each raw material components respectively, after pulverizing respectively, obtaining granularity is the 60 each raw material fine powders of purpose；
(2) carry out described each raw material fine powder being sufficiently mixed uniformly, obtain the drug regimen of described protection eye eyesight
Thing.
Embodiment 2
The present embodiment provides a kind of conventional tablet protecting eye eyesight, and raw material components includes:
Phylloxanthin, 60 weight portions；
Haematocoocus Pluvialls, 255 weight portions；
Vitamin E, 40 weight portions；
Vitamin C, 115 weight portions；
Zinc gluconate, 95 weight portions；
Microcrystalline Cellulose, 70 weight portions；
Polyvinylpolypyrrolidone, 50 weight portions；
Hydroxypropyl methyl cellulose, 30 weight portions；
Magnesium stearate, 6 weight portions.
The preparation method of the tablet of described protection eye eyesight, comprises the steps:
(1) phylloxanthin, Haematocoocus Pluvialls, vitamin E, vitamin C, zinc gluconate, microcrystalline Cellulose, friendship are weighed respectively
Connection polyvidone, hydroxypropyl methyl cellulose, after pulverizing respectively, obtaining granularity is the 100 each raw material fine powders of purpose；
(2) carry out described for step (1) each raw material fine powder being sufficiently mixed uniformly, obtain mixed powder；
(3) in step (2) described mixed powder, add the ethanol that volumetric concentration is 80% of 0.1 times of quality, make granularity
It is the 20 wet grains of purpose；
(4) described wet grain is dried 20min at 60 DEG C and obtains dry granular, and the moisture content of described dry granular is 4%；By described dry
Grain uses the sieve of 20 mesh to carry out granulate, adds described magnesium stearate afterwards, carries out tabletting, obtains described protection eye eyesight
The conventional tablet of pharmaceutical composition.
Embodiment 3
The present embodiment provides a kind of coated tablet protecting eye eyesight, and raw material components includes:
Phylloxanthin, 80 weight portions；
Haematocoocus Pluvialls, 230 weight portions；
Vitamin E, 50 weight portions；
Vitamin C, 135 weight portions；
Zinc gluconate, 80 weight portions；
Amylum pregelatinisatum, 100 weight portions；
Sodium starch glycollate, 80 weight portions；
Carbomer, 20 weight portions；
Magnesium laurylsulfate, 2 weight portions.
The preparation method of the coated tablet of described protection eye eyesight, comprises the steps:
(1) phylloxanthin, Haematocoocus Pluvialls, vitamin E, vitamin C, zinc gluconate, amylum pregelatinisatum, hydroxyl are weighed respectively
Guanidine-acetic acid Starch Sodium, carbomer, after pulverizing respectively, obtaining granularity is the 80 each raw material fine powders of purpose；
(2) carry out described for step (1) each raw material fine powder being sufficiently mixed uniformly, obtain mixed powder；
(3) in step (2) described mixed powder, add the ethanol that volumetric concentration is 75% of 0.2 times of quality, make granularity
It is the 18 wet grains of purpose；
(4) described wet grain is dried 30min at 55 DEG C and obtains dry granular, and the moisture content of described dry granular is 4%；By described dry
Grain uses the sieve of 16 mesh to carry out granulate；Add described magnesium laurylsulfate afterwards, carry out tabletting, obtain tablet, by described tablet
Add in seed-coating machine, injection film coating slurry, obtain coated tablet.
Embodiment 4
The present embodiment provides a kind of pill protecting eye eyesight, and raw material components includes:
Phylloxanthin, 100 weight portions；
Haematocoocus Pluvialls, 200 weight portions；
Vitamin E, 60 weight portions；
Vitamin C, 100 weight portions；
Zinc gluconate, 70 weight portions；
Sorbitol, 140 weight portions；
Polyvinylpolypyrrolidone, 65 weight portions；
Hydroxypropyl methyl cellulose, 40 weight portions；
Magnesium stearate, 2 weight portions.
The preparation method of the pill of described protection eye eyesight, comprises the steps:
(1) phylloxanthin, Haematocoocus Pluvialls, vitamin E, vitamin C, zinc gluconate are weighed respectively, after pulverizing respectively,
Obtaining granularity is the 80 each raw material fine powders of purpose；
(2) carry out described for step (1) each raw material fine powder being sufficiently mixed uniformly, obtain mixed powder；
(3) in step (2) described mixed powder, it is sequentially added into described sorbitol, polyvinylpolypyrrolidone, hydroxypropyl methyl fiber
Element and magnesium stearate, be sufficiently mixed uniformly, make pill.
Embodiment 5
The present embodiment provides a kind of hard capsule protecting eye eyesight, and raw material components includes:
Phylloxanthin, 120 weight portions；
Haematocoocus Pluvialls, 175 weight portions；
Vitamin E, 70 weight portions；
Vitamin C, 85 weight portions；
Zinc gluconate, 60 weight portions；
Mannitol, 120 weight portions；
Polyvinylpolypyrrolidone, 70 weight portions；
Hydroxypropyl cellulose, 25 weight portions；
Micropowder silica gel, 4 weight portions.
The preparation method of the hard capsule of described protection eye eyesight, comprises the steps:
(1) phylloxanthin, Haematocoocus Pluvialls, vitamin E, vitamin C, zinc gluconate are weighed respectively, after pulverizing respectively,
Obtaining granularity is the 80 each raw material fine powders of purpose；
(2) carry out described for step (1) each raw material fine powder being sufficiently mixed uniformly, obtain mixed powder；
(3) be sequentially added in step (2) described mixed powder described mannitol, polyvinylpolypyrrolidone, hydroxypropyl cellulose and
Micropowder silica gel, is sufficiently mixed uniformly, fills in hollow hard capsules and make hard capsule.
Embodiment 6
The present embodiment provides a kind of conventional tablet protecting eye eyesight, and raw material components includes:
Phylloxanthin, 140 weight portions；
Haematocoocus Pluvialls, 145 weight portions；
Vitamin E, 80 weight portions；
Vitamin C, 65 weight portions；
Zinc gluconate, 45 weight portions；
Macrogol 4000,130 weight portions；
Cross-linking sodium carboxymethyl cellulose, 50 weight portions；
Sodium carboxymethyl cellulose, 40 weight portions；
Pulvis Talci, 6 weight portions.
The preparation method of the tablet of described protection eye eyesight, comprises the steps:
(1) weigh respectively phylloxanthin, Haematocoocus Pluvialls, vitamin E, vitamin C, zinc gluconate, Macrogol 4000,
Cross-linking sodium carboxymethyl cellulose, sodium carboxymethyl cellulose, after pulverizing respectively, obtaining granularity is the 80 each raw material fine powders of purpose；
(2) carry out described for step (1) each raw material fine powder being sufficiently mixed uniformly, obtain mixed powder；
(3) in step (2) described mixed powder, add the ethanol that volumetric concentration is 75% of 0.18 times of quality, make granularity
It is the 18 wet grains of purpose；
(4) described wet grain is dried 20min at 55 DEG C and obtains dry granular, and the moisture content of described dry granular is 3%；By described dry
Grain uses the sieve of 16 mesh to carry out granulate, adds described Pulvis Talci afterwards, carries out tabletting, obtains the medicine of described protection eye eyesight
The conventional tablet of compositions.
Embodiment 7
The present embodiment provides a kind of soft capsule protecting eye eyesight, and raw material components includes:
Phylloxanthin, 100 weight portions；
Haematocoocus Pluvialls, 175 weight portions；
Vitamin E, 60 weight portions；
Vitamin C, 135 weight portions；
Zinc gluconate, 80 weight portions；
Glycerol, 180 weight portions；
Polyvidone, 30 weight portions；
Lecithin, 55 weight portions.
The preparation method of the tablet of described protection eye eyesight, comprises the steps:
(1) phylloxanthin, Haematocoocus Pluvialls, vitamin E, vitamin C, zinc gluconate are weighed respectively, after pulverizing respectively,
Obtaining granularity is the 80 each raw material fine powders of purpose；
(2) carry out described for step (1) each raw material fine powder being sufficiently mixed uniformly, obtain mixed powder；
(3) in step (2) described mixed powder, add described glycerol, polyvidone, lecithin, be sufficiently mixed and uniformly prepare medicine
Liquid, instills medicinal liquid in hollow soft capsule and makes soft capsule.
Embodiment 8
The present embodiment provides a kind of soft capsule protecting eye eyesight, and raw material components includes:
Phylloxanthin, 120 weight portions；
Haematocoocus Pluvialls, 200 weight portions；
Vitamin E, 80 weight portions；
Vitamin C, 115 weight portions；
Zinc gluconate, 60 weight portions；
Glycerol, 260 weight portions；
Polyvidone, 10 weight portions；
Lecithin, 40 weight portions.
The preparation method of the tablet of described protection eye eyesight, comprises the steps:
(1) phylloxanthin, Haematocoocus Pluvialls, vitamin E, vitamin C, zinc gluconate are weighed respectively, after pulverizing respectively,
Obtaining granularity is the 80 each raw material fine powders of purpose；
(2) carry out described for step (1) each raw material fine powder being sufficiently mixed uniformly, obtain mixed powder；
(3) in step (2) described mixed powder, add described glycerol, polyvidone, lecithin, be sufficiently mixed and uniformly prepare medicine
Liquid, instills medicinal liquid in hollow soft capsule and makes soft capsule.
Embodiment 9
The present embodiment provides a kind of soft capsule protecting eye eyesight, and raw material components includes:
Phylloxanthin, 80 weight portions；
Haematocoocus Pluvialls, 230 weight portions；
Vitamin E, 60 weight portions；
Vitamin C, 85 weight portions；
Zinc gluconate, 45 weight portions；
Glycerol, 220 weight portions；
Polyvidone, 20 weight portions；
Lecithin, 55 weight portions.
The preparation method of the tablet of described protection eye eyesight, comprises the steps:
(1) phylloxanthin, Haematocoocus Pluvialls, vitamin E, vitamin C, zinc gluconate are weighed respectively, after pulverizing respectively,
Obtaining granularity is the 80 each raw material fine powders of purpose；
(2) carry out described for step (1) each raw material fine powder being sufficiently mixed uniformly, obtain mixed powder；
(3) in step (2) described mixed powder, add described glycerol, polyvidone, lecithin, be sufficiently mixed and uniformly prepare medicine
Liquid, instills medicinal liquid in hollow soft capsule and makes soft capsule.
Experimental example
The present inventor by applying the observation of this pharmaceutical composition, wherein male 50 to clinical 100 example disease of eye patients
Example, women 50 example, minimum 39 years old of age, maximum 81 years old.
Application process: oral, every day each 1 time sooner or later, each 15g of dose.
Efficacy assessment standard:
Cure: clinical efficacy is notable, and symptom is wholly absent, 68 examples.
Effective: clinical symptoms is controlled, symptom is obviously improved, 27 examples.
Invalid: clinical symptoms is not improved 5 examples.Total effective rate 95%.
Typical clinical case:
Mr. Liu, 61 years old, eye macular area lacked phylloxanthin, suffers from senile degeneration of macula.Simultaneously as vitreous body mixes
Turbid, there is stain at the moment.Taking the medicine 1 month of the embodiment of the present invention 4, vision makes moderate progress, after taking 6 months continuously, and eyes
Bright, central region will also recognize that, stain at the moment also disappears.
Mrs Du, 56 years old, because lenticular opacities suffers from slight cataract, has cloud, at the moment depending on thing ghost image.Take this
The medicine of bright embodiment 51 month, eyestrain sense declines, and after taking 3 months continuously, cloud and mist at the moment disappears, and sees that thing is clear
Chu is many, no longer has ghost image.
Mr. Chen, 57 years old, found before 3 years and suffers from diabetes, owing to blood sugar concentration is too high, change Vascular Permeability,
Cells of vascular wall is atrophy because of dehydration, narrowed blood vessels, and eyes local vascular blood supply and oxygen supply reduce, and eyes are because of anoxia and nutrition not
Foot, causes vision more and more weak, metamorphopsia.Taking the medicine of the embodiment of the present invention 7 after 1 month, vision no longer deteriorates, and takes
After 3 months, vision substantially has improvement, and after taking 6 months, eyes are bright how, see that thing is the most normal.
Miss Wang, 34 years old, owing to all day handles official business before computer, overtime work caught up with file often to occur, and eyes are the most uncomfortable, sense
Feel there is the thing as cotton-wool at the moment, and eyes always distending pain.Take one week of medicine of embodiments of the invention 9,
Sensation eyes are comfortable how, and after taking 1 month continuously, the thing of cotton-wool sample is wholly absent at the moment, and overtime work is not felt to feel bad
?.
The present invention is not limited to above-mentioned preferred forms, and anyone can show that under the enlightenment of the present invention other are various
The product of form, no matter but in its shape or structure, make any change, every have same as the present application or akin skill
Art scheme, within all falling within protection scope of the present invention.
Claims (10)
1. the pharmaceutical composition protecting eye eyesight, it is characterised in that raw material components includes:
Phylloxanthin, 60-140 weight portion；
Haematocoocus Pluvialls, 145-255 weight portion；
Vitamin E, 40-80 weight portion；
Vitamin C, 65-135 weight portion；
Zinc gluconate, 45-95 weight portion.
The pharmaceutical composition of protection eye eyesight the most according to claim 1, it is characterised in that raw material components includes:
Phylloxanthin, 80-120 weight portion；
Haematocoocus Pluvialls, 175-230 weight portion；
Vitamin E, 50-70 weight portion；
Vitamin C, 85-115 weight portion；
Zinc gluconate, 60-80 weight portion.
The pharmaceutical composition of protection eye eyesight the most according to claim 1, it is characterised in that raw material components includes:
Phylloxanthin, 100 weight portions；
Haematocoocus Pluvialls, 200 weight portions；
Vitamin E, 60 weight portions；
Vitamin C, 100 weight portions；
Zinc gluconate, 70 weight portions.
The pharmaceutical composition of protection eye eyesight the most according to claim 1, it is characterised in that raw material components is also added with
70-140 parts by weight of filler, 50-80 part by weight of disintegrant, 20-40 parts by weight of binder and 2-6 weight portion lubricant.
The pharmaceutical composition of protection eye eyesight the most according to claim 1, it is characterised in that raw material components is also added with
The mixing of one or more in 180-260 parts by weight diluent, 10-30 weight portion cosolvent and 40-70 parts by weight Emulsifier
Thing.
The pharmaceutical composition of protection eye eyesight the most according to claim 4, it is characterised in that described filler is crystallite
Cellulose, sorbitol, Macrogol 4000, polyethylene glycol 6000, mannitol, amylum pregelatinisatum, dextrin, lactose, starch, modification
The mixture that one or more in starch form with arbitrary proportion；
Described disintegrating agent is polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, starch glycolate NF
The mixture that one or more in sodium or carboxymethyl starch sodium form with arbitrary proportion；
Described binding agent is hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, polyvidone, methylcellulose, hydroxy propyl cellulose
The mixture that one or more in element, ethyl cellulose, gelatin, carbomer or starch slurry form with arbitrary proportion；
Described lubricant is magnesium stearate, Pulvis Talci, micropowder silica gel, silicon dioxide, PEG6000, fumaric acid sodium, lauryl alcohol sulphuric acid
The mixture that one or more in magnesium or sodium laurylsulfate form with arbitrary proportion.
The pharmaceutical composition of protection eye eyesight the most according to claim 5, it is characterised in that described diluent is sweet
Oil, sorbitol, decanoyl/octanoyl glycerides, soybean oil, one or more mixture formed with arbitrary proportion of PEG400；
Described cosolvent be glycerol, polyvidone, cyclodextrin, isopropanol, ethylenediamine, lactic acid, polysorbate 20, polysorbate 85,
The mixture that one or more in polypropylene glycol form with arbitrary proportion；
Described emulsifying agent is sodium lauryl sulphate, dodecylbenzene sodium sulfonate, Stepanol MG, myristyl sulfate
One in sodium, lecithin, emulsifing wax, Cera Flava, casein, ethylene glycol monostearate, polysorbate 20, polysorbate 85 or
Several mixture formed with arbitrary proportion.
8. the method for the pharmaceutical composition of the protection eye eyesight that a kind is prepared described in claim 4 or 6, it is characterised in that bag
Include following steps:
(1) weighing each raw material components respectively, after pulverizing respectively, obtaining granularity is each raw material fine powder of 60-100 purpose；
(2) carry out described for step (1) each raw material fine powder being sufficiently mixed uniformly, obtain the medicine group of described protection eye eyesight
Compound.
9. the method for the pharmaceutical composition of the protection eye eyesight that a kind is prepared described in claim 5 or 7, it is characterised in that bag
Include following steps:
(1) weigh phylloxanthin, Haematocoocus Pluvialls, vitamin E, vitamin C, zinc gluconate respectively, after pulverizing respectively, obtain
Granularity is each raw material fine powder of 60-100 purpose；
(2) carry out described for step (1) each raw material fine powder being sufficiently mixed uniformly, obtain compound；
(3) in step (2) described compound, it is sequentially added into described diluent, cosolvent and emulsifying agent, obtains described protection
The pharmaceutical composition of eye eyesight.
10. the pharmaceutical composition described in any one of claim 1-7 is for preparing the application in protection eye eyesight medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610500492.XA CN106038612A (en) | 2016-06-29 | 2016-06-29 | Pharmaceutical composition for protecting eyesight as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610500492.XA CN106038612A (en) | 2016-06-29 | 2016-06-29 | Pharmaceutical composition for protecting eyesight as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106038612A true CN106038612A (en) | 2016-10-26 |
Family
ID=57200298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610500492.XA Pending CN106038612A (en) | 2016-06-29 | 2016-06-29 | Pharmaceutical composition for protecting eyesight as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106038612A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108042504A (en) * | 2017-12-15 | 2018-05-18 | 拜尔普兰（厦门）生物药业有限公司 | A kind of lutein tablet composition and preparation method thereof |
| CN108634303A (en) * | 2018-05-15 | 2018-10-12 | 杭州鑫伟低碳技术研发有限公司 | It is a kind of prevent, the product and preparation method thereof of auxiliary treatment disease of eye |
| CN108669551A (en) * | 2018-04-25 | 2018-10-19 | 杭州鑫伟低碳技术研发有限公司 | A kind of product and preparation method thereof for improving xerophthalmia, fundus flavimaculatus |
| CN109663122A (en) * | 2019-01-22 | 2019-04-23 | 夏洪峰 | It is a kind of to provide nutrition, improvement eyesight, the composition grain electuary for preventing eye disease and preparation method thereof for macula retinae area |
| CN110037218A (en) * | 2019-05-06 | 2019-07-23 | 云南爱尔康生物技术有限公司 | Improve the haematococcus pluvialis lutein solid drink and preparation method thereof of visual fatigue |
| CN110179838A (en) * | 2019-06-13 | 2019-08-30 | 杭州鑫伟低碳技术研发有限公司 | A kind of spread product preventing and treating visual fatigue |
| CN113331420A (en) * | 2021-06-21 | 2021-09-03 | 北京兰厚化妆品有限责任公司 | Composition for protecting eyes, health food and preparation method thereof |
| WO2023058123A1 (en) * | 2021-10-05 | 2023-04-13 | ＢＧＧ Ｊａｐａｎ株式会社 | Composition for visual-acuity improvement |
| US11696593B2 (en) | 2018-08-24 | 2023-07-11 | Bioscience Formulators, LLC | Astaxanthin nutritional compositions and uses |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389115A (en) * | 2011-11-03 | 2012-03-28 | 云南绿A生物工程有限公司 | Health food for alleviating visual fatigue and preparation method and application thereof |
| CN104824675A (en) * | 2015-05-13 | 2015-08-12 | 宁波北仑戌鸿农业科技有限公司 | Eyesight improving lutein capsule |
-
2016
- 2016-06-29 CN CN201610500492.XA patent/CN106038612A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389115A (en) * | 2011-11-03 | 2012-03-28 | 云南绿A生物工程有限公司 | Health food for alleviating visual fatigue and preparation method and application thereof |
| CN104824675A (en) * | 2015-05-13 | 2015-08-12 | 宁波北仑戌鸿农业科技有限公司 | Eyesight improving lutein capsule |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108042504A (en) * | 2017-12-15 | 2018-05-18 | 拜尔普兰（厦门）生物药业有限公司 | A kind of lutein tablet composition and preparation method thereof |
| CN108669551A (en) * | 2018-04-25 | 2018-10-19 | 杭州鑫伟低碳技术研发有限公司 | A kind of product and preparation method thereof for improving xerophthalmia, fundus flavimaculatus |
| CN108634303A (en) * | 2018-05-15 | 2018-10-12 | 杭州鑫伟低碳技术研发有限公司 | It is a kind of prevent, the product and preparation method thereof of auxiliary treatment disease of eye |
| US11696593B2 (en) | 2018-08-24 | 2023-07-11 | Bioscience Formulators, LLC | Astaxanthin nutritional compositions and uses |
| CN109663122A (en) * | 2019-01-22 | 2019-04-23 | 夏洪峰 | It is a kind of to provide nutrition, improvement eyesight, the composition grain electuary for preventing eye disease and preparation method thereof for macula retinae area |
| CN110037218A (en) * | 2019-05-06 | 2019-07-23 | 云南爱尔康生物技术有限公司 | Improve the haematococcus pluvialis lutein solid drink and preparation method thereof of visual fatigue |
| CN110179838A (en) * | 2019-06-13 | 2019-08-30 | 杭州鑫伟低碳技术研发有限公司 | A kind of spread product preventing and treating visual fatigue |
| CN113331420A (en) * | 2021-06-21 | 2021-09-03 | 北京兰厚化妆品有限责任公司 | Composition for protecting eyes, health food and preparation method thereof |
| WO2023058123A1 (en) * | 2021-10-05 | 2023-04-13 | ＢＧＧ Ｊａｐａｎ株式会社 | Composition for visual-acuity improvement |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106038612A (en) | Pharmaceutical composition for protecting eyesight as well as preparation method and application thereof | |
| CN103735733B (en) | A kind of compound preparation containing lutein ester and preparation method thereof | |
| CN109091675B (en) | Compound low-concentration atropine medicine eye drops and preparation method thereof | |
| CN101199526A (en) | Improving eyesight guard inspect health care preparation and preparing method thereof | |
| CN102763847B (en) | Health-care food with function of relieving visual fatigue and preparation method thereof | |
| CN103566049B (en) | Regard the composition of macular degeneration disease in eyes regarding macular pigment optical density and prevention or treatment age related for improving | |
| CN108157568A (en) | A kind of Combined candy for alleviating visual fatigue and its preparation method and application | |
| CN102144780A (en) | Lutein ester health care product for protecting eyesight and preparation method thereof | |
| CN103609972A (en) | Health-care noodle containing Chinese herbal medicine formula and production technology thereof | |
| CN104147081A (en) | Blueberry lutein soft capsule for improving eyesight and manufacturing method thereof | |
| CN104225265B (en) | A kind of Traditional Chinese medicine composition for relieving asthenopia | |
| CN103300373A (en) | Lutein and procyanidine composite soft capsule and preparation method thereof | |
| CN110169484A (en) | A kind of blueberry lutein ester pressed candy and preparation method thereof | |
| CN109430856A (en) | A kind of eye-protecting improves the Ricipe for health care food and preparation method thereof of visual fatigue | |
| CN102166203A (en) | Eye pad for alleviating eye fatigue and preparation method thereof | |
| CN105520137B (en) | It is a kind of that there is the health food alleviated visual fatigue and protect visual function | |
| CN105983004A (en) | Composition capable of alleviating asthenopia and preparation method | |
| CN105106286A (en) | Health product with effects of protecting eyes and improving eyesight | |
| CN108324705A (en) | Composition for relieving asthenopia containing theanine, γ-aminobutyric acid and anthocyanidin | |
| CN100457150C (en) | Capsule or tablet for relieving vision fatigue and preparing method | |
| CN102150860B (en) | Composition for easing visual fatigue and assisting in improving memory | |
| CN109865016A (en) | A kind of pharmaceutical composition and its preparation method and application for treating xerophthalmia | |
| CN104161260A (en) | Composition used for relieving asthenopia and preparation method thereof | |
| EP2262515B1 (en) | Black soybean product for treating of ophthalmic diseases | |
| CN105147709B (en) | A kind of purposes of tenofovir dipivoxil or its pharmaceutical salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161026 |
|
| RJ01 | Rejection of invention patent application after publication |